Suzana Jordan1, James Chung, Oliver Distler. 1. aDepartment of Rheumatology, University Hospital Zurich, Zurich, Switzerland bAmgen Inc., Thousand Oaks, California, USA.
Abstract
PURPOSE OF REVIEW: To discuss the strategies for preclinical and early clinical characterization of targeted antifibrotic therapies in order to optimize the probability of positive results in later stage clinical trials. RECENT FINDINGS: There is a high unmet clinical need for effective antifibrotic therapies in systemic sclerosis (SSc), and in parallel a rapid development in the identification of potential molecular targets in preclinical research. Herein, we discuss the strategies for the improvement of preclinical and early clinical trials. These strategies include identification and characterization of molecular targets for therapy in vitro, selection of relevant parameters in translational animal models, confirmation of target activation in human SSc, analysis of successful target coverage after drug exposure in human SSc, and conduct of biomarker-driven proof-of-concept studies as a bridge between animal studies and Phase IIB/III studies with clinical endpoints. SUMMARY: These strategies could increase the possibility to develop successful drugs against the fibrotic manifestations of SSc.
PURPOSE OF REVIEW: To discuss the strategies for preclinical and early clinical characterization of targeted antifibrotic therapies in order to optimize the probability of positive results in later stage clinical trials. RECENT FINDINGS: There is a high unmet clinical need for effective antifibrotic therapies in systemic sclerosis (SSc), and in parallel a rapid development in the identification of potential molecular targets in preclinical research. Herein, we discuss the strategies for the improvement of preclinical and early clinical trials. These strategies include identification and characterization of molecular targets for therapy in vitro, selection of relevant parameters in translational animal models, confirmation of target activation in human SSc, analysis of successful target coverage after drug exposure in human SSc, and conduct of biomarker-driven proof-of-concept studies as a bridge between animal studies and Phase IIB/III studies with clinical endpoints. SUMMARY: These strategies could increase the possibility to develop successful drugs against the fibrotic manifestations of SSc.
Authors: Laetitia Ledein; Bertrand Léger; Clara Dees; Christian Beyer; Alfiya Distler; Serena Vettori; Rachid Boukaiba; Jean Pierre Bidouard; Matthias Schaefer; Josef Pernerstorfer; Hartmut Ruetten; Alexandre Jagerschmidt; Philip Janiak; Jörg H W Distler; Oliver Distler; Stéphane Illiano Journal: Br J Pharmacol Date: 2020-08-05 Impact factor: 8.739